416 related articles for article (PubMed ID: 33220125)
21. Resistant cytomegalovirus in intestinal and multivisceral transplant recipients.
Timpone JG; Yimen M; Cox S; Teran R; Ajluni S; Goldstein D; Fishbein T; Kumar PN; Matsumoto C
Transpl Infect Dis; 2016 Apr; 18(2):202-9. PubMed ID: 26853894
[TBL] [Abstract][Full Text] [Related]
22. Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients.
Noble S; Faulds D
Drugs; 1998 Jul; 56(1):115-46. PubMed ID: 9664203
[TBL] [Abstract][Full Text] [Related]
23. New Treatment Options for Refractory/Resistant CMV Infection.
Walti CS; Khanna N; Avery RK; Helanterä I
Transpl Int; 2023; 36():11785. PubMed ID: 37901297
[TBL] [Abstract][Full Text] [Related]
24. Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipients.
Li F; Kenyon KW; Kirby KA; Fishbein DP; Boeckh M; Limaye AP
Clin Infect Dis; 2007 Aug; 45(4):439-47. PubMed ID: 17638191
[TBL] [Abstract][Full Text] [Related]
25. Molecular Epidemiology of Cytomegalovirus UL97 and UL54 variants in Taiwan.
Yang SL; Lin TW; Lin HC; Wang HY; Chang PY; Wang PN; Yang S; Lu JJ
J Microbiol Immunol Infect; 2021 Oct; 54(5):971-978. PubMed ID: 33632621
[TBL] [Abstract][Full Text] [Related]
26. Cidofovir, a choice for salvage treatment of cytomegalovirus infection in patients with haploidentical hematopoietic stem cell transplantation.
Yin Z; Sun J; Yang Y; Xu N; Jiang L; Fan Z; Huang F; Shi P; Wang Z; Xuan L; Xu J; Liu Q; Yu G
Transpl Infect Dis; 2022 Apr; 24(2):e13776. PubMed ID: 34941004
[TBL] [Abstract][Full Text] [Related]
27. Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir.
Boivin G; Goyette N; Rollag H; Jardine AG; Pescovitz MD; Asberg A; Ives J; Hartmann A; Humar A
Antivir Ther; 2009; 14(5):697-704. PubMed ID: 19704173
[TBL] [Abstract][Full Text] [Related]
28. Ganciclovir-Resistant Cytomegalovirus Infection in Abdominal Solid Organ Transplant Recipients: Case Series and Review of the Literature.
Rolling KE; Jorgenson MR; Descourouez JL; Mandelbrot DA; Redfield RR; Smith JA
Pharmacotherapy; 2017 Oct; 37(10):1258-1271. PubMed ID: 28699311
[TBL] [Abstract][Full Text] [Related]
29. Cytomegalovirus infection and ganciclovir resistance caused by UL97 mutations in pediatric transplant recipients.
Kim YJ; Boeckh M; Cook L; Stempel H; Jerome KR; Boucek R; Burroughs L; Englund JA
Transpl Infect Dis; 2012 Dec; 14(6):611-7. PubMed ID: 23198963
[TBL] [Abstract][Full Text] [Related]
30. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes.
Eid AJ; Arthurs SK; Deziel PJ; Wilhelm MP; Razonable RR
Clin Transplant; 2008; 22(2):162-70. PubMed ID: 18339135
[TBL] [Abstract][Full Text] [Related]
31. Selection and recombinant phenotyping of a novel CMX001 and cidofovir resistance mutation in human cytomegalovirus.
James SH; Price NB; Hartline CB; Lanier ER; Prichard MN
Antimicrob Agents Chemother; 2013 Jul; 57(7):3321-5. PubMed ID: 23650158
[TBL] [Abstract][Full Text] [Related]
32. Management of allogeneic bone marrow transplant recipients at risk for cytomegalovirus disease using a surveillance bronchoscopy and prolonged pre-emptive ganciclovir therapy.
Reddy V; Hao Y; Lipton J; Meharchand J; Minden M; Mazzulli T; Chan C; Messner HA
J Clin Virol; 1999 Aug; 13(3):149-59. PubMed ID: 10443791
[TBL] [Abstract][Full Text] [Related]
33. Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis.
Martin M; Goyette N; Ives J; Boivin G
J Clin Virol; 2010 Apr; 47(4):321-4. PubMed ID: 20138805
[TBL] [Abstract][Full Text] [Related]
34. Clinical characteristics of 13 solid organ transplant recipients with ganciclovir-resistant cytomegalovirus infection.
Isada CM; Yen-Lieberman B; Lurain NS; Schilz R; Kohn D; Longworth DL; Taege AJ; Mossad SB; Maurer J; Flechner SM; Mawhorter SD; Braun W; Gordon SM; Schmitt SK; Goldman M; Long J; Haug M; Avery RK
Transpl Infect Dis; 2002 Dec; 4(4):189-94. PubMed ID: 12535261
[TBL] [Abstract][Full Text] [Related]
35. A Case Report of Successful Use of Twice-Daily Letermovir in the Treatment of Resistant Cytomegalovirus in a Small Bowel Transplant Recipient.
Joharji H; Alaidaros F; Koujan H; Hamad A; Almaghrabi RS; Zidan A; Broering D; Al-Jedai A
Transplant Proc; 2022; 54(6):1679-1681. PubMed ID: 35842318
[TBL] [Abstract][Full Text] [Related]
36. Impact of donor and recipient cytomegalovirus serology on long-term survival of heart transplant recipients.
Mabilangan C; Preiksaitis JK; Cervera C;
Transpl Infect Dis; 2019 Feb; 21(1):e13015. PubMed ID: 30358023
[TBL] [Abstract][Full Text] [Related]
37. Successful treatment with foscarnet for ganciclovir-resistant cytomegalovirus infection in a kidney transplant recipient: A case report.
Iwami D; Ogawa Y; Fujita H; Morita K; Sasaki H; Oishi Y; Higuchi H; Hatanaka K; Shinohara N
Nephrology (Carlton); 2016 Jul; 21 Suppl 1():63-6. PubMed ID: 26970406
[TBL] [Abstract][Full Text] [Related]
38. Antiviral treatment of cytomegalovirus infection.
Ahmed A
Infect Disord Drug Targets; 2011 Oct; 11(5):475-503. PubMed ID: 21827432
[TBL] [Abstract][Full Text] [Related]
39. A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome.
Reddy AJ; Zaas AK; Hanson KE; Palmer SM
J Heart Lung Transplant; 2007 Dec; 26(12):1286-92. PubMed ID: 18096480
[TBL] [Abstract][Full Text] [Related]
40. Recurrent and persistent cytomegalovirus infection in a kidney recipient caused by the L595S mutation in UL97 phosphotransferase gene.
Peixoto M; Mascarenhas L; Cunha A; Dutra M; Miranda E; Silva I; Costa S; Galvão B; Cunha A
Antivir Ther; 2012; 17(3):585-8. PubMed ID: 22293247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]